(TheNewswire)
L ondon , ON - TheNewswire- August9 ,2021 - SernovaCorp . (TSXV:SVA) (FSE/XETRA:PSH) (OTC:SEOVF), a leading clinical-stage company focused on regenerativemedicine therapeutics, today announced that Dr. Philip Toleikis,President and CEO, will provide a corporate update at CanaccordGenuity’s 41 st Annual Growth Conference on Wednesday,August 11 th , 2021 at 9:30am EDT.
Dr. Toleikis said, “The opportunity to present atCanaccord Genuity’s 41 st Annual Growth Conference furthers ouragenda to expand awareness among US investors, institutions, andbankers. This presentation will highlight Sernova’s recent clinicaladvancements and collaborations, and we will share the unprecedentedpotential of our cellular therapeutics platform to transform thetreatment and management of chronic diseases, such as diabetes,hemophilia, and hypothyroidism. As one example, in our ongoing USPhase I/II diabetes clinical trial, our first patient has completedthe study protocol and achieved complete insulin independence for over15 months (and counting). These interim clinical findings demonstratenot only clinical benefit in a brittle diabetic population but that a‘functional cure’ may be achievable for these patients.”
Management will be available throughout the conferencefor virtual one-on-one meetings. Investors interested in arranging ameeting with the Company’s management during the conference shouldcontact the Canaccord Genuity conference coordinator.
Webcast Link:
A live webcast of Sernova’s presentation session willbe available under ‘Featured News’ on the Company’s websiteat https://www.sernova.com/press
ABOUT SERNOVA
Sernova is developing regenerative medicine therapeutic technologiesusing a medical device and immune protected therapeutic cells (i.e.human donor cells, corrected human cells and stem cell-derived cells)to improve the treatment and quality of life of people with chronicmetabolic diseases such as insulin-dependent diabetes, blood disordersincluding hemophilia, and other diseases treated through replacementof proteins or hormones missing or in short supply within the body.For more information, please visit www.sernova.com .
FOR FURTHER INFORMATION, PLEASE CONTACT:
Investor Relations
Sernova Corp.
Tel: (519) 858-5126
investorrelations@sernova.com
www.sernova.com
This release contains statements that, to the extentthey are not recitations of historical facts, may constitute“forward-looking statements” that involve various risks,uncertainties, and assumptions, including, without limitation,statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always,words such as "expects", "plans","anticipates", "believes", "intends","estimates", "projects", "potential for"and similar expressions, or that events or conditions"will", "would", "may","could" or "should" occur are used to identifyforward-looking statements. These statements reflect management’sbeliefs with respect to future events, including results of clinicaltrials, and are based on information currently available to managementon the date such statements were made. Many factors could causeSernova’s actual results, performances or achievements to not be asanticipated, estimated or intended or to differ materially from thoseexpressed or implied by the forward-looking statements contained inthis news release. Many of the factors are beyond our control,including those caused by, related to, or impacted by the novelcoronavirus pandemic. Investors should consult the company’squarterly and annual filings available on www.sedar.com for additionalinformation on risks and uncertainties relating to the forward-lookingstatements. Sernova expressly disclaims any intention or obligation toupdate or revise any forward-looking statements, whether as a resultof new information, future events or otherwise.
Copyright (c) 2021 TheNewswire - All rights reserved.